How to Prevent Neuropathy From Chemo

No drug or supplement has been proven to prevent chemotherapy-induced peripheral neuropathy (CIPN), and the leading oncology guideline explicitly states that no agent can be recommended for that purpose. That is the frustrating reality confirmed by the American Society of Clinical Oncology’s most recent guideline update on the topic. But “no proven prevention” does not mean “nothing you can do.” A handful of strategies, from exercise during treatment to careful dose management and emerging physical interventions, can lower the odds of severe nerve damage or catch it early enough to change course. The challenge is knowing which of these are backed by real evidence and which are wishful thinking.

Why This Problem Is So Hard to Solve

CIPN develops because many of the most effective chemotherapy drugs damage peripheral nerves as a side effect of killing cancer cells. Taxanes like paclitaxel, platinum agents like oxaliplatin and cisplatin, and vinca alkaloids like vincristine are among the worst offenders. The nerve damage involves multiple overlapping processes, including oxidative stress, inflammation, disrupted calcium balance inside nerve cells, and direct destruction of axons. ¹ Because the damage comes from so many directions simultaneously, blocking a single pathway has not been enough to protect nerves.

The symptoms are familiar to anyone who has experienced them: tingling, numbness, burning, or shooting pain in the hands and feet, sometimes spreading up the arms and legs. Fine motor tasks become difficult. Buttons, zippers, and writing get harder. Balance suffers. And for a meaningful number of people, the damage does not fully reverse. Roughly 30% of patients still have CIPN a year or more after finishing chemotherapy. ² In patients treated with oxaliplatin for colorectal cancer, one study found neuropathy still present in about 69% of patients at a median follow-up of just over four years. ³ A phenomenon called “coasting” can even cause symptoms to worsen after treatment ends. ⁴

Who Faces the Highest Risk

Not everyone on neurotoxic chemotherapy develops severe neuropathy, and understanding your individual risk is one of the most practical things you can do. In a study of patients receiving taxane- or platinum-based chemotherapy, several factors stood out in statistical models. Older age increased the risk. Each additional chemotherapy cycle raised the odds. Having a pre-existing neuropathy from any cause, such as diabetes, dramatically raised the chance of motor neuropathy. And the type of drug mattered: taxane-based regimens carried a higher risk than platinum-based ones in that particular comparison. ⁵

Your genetic makeup also plays a role, though this is not yet useful for routine clinical decisions. Researchers have found that variations in genes involved in drug metabolism, ion channel function, and DNA repair can influence how severe your neuropathy becomes. Some gene combinations have been linked to a two- to fivefold increase in the risk of severe oxaliplatin-induced neuropathy. ⁶ The hope is that pharmacogenetic testing will eventually help oncologists tailor regimens to individual vulnerability, but for now, these findings are mostly research tools. ⁷

If you already have neuropathy from diabetes, alcohol use, or another condition, make sure your oncologist knows. That pre-existing damage puts you at substantially higher baseline risk and may influence which chemo regimen or dose schedule your team selects.

Dose Adjustments and Early Monitoring

Since no preventive drug has passed the evidence bar, the ASCO guideline’s most practical recommendation is that oncologists should “assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment.” ⁸ In plain terms, catching neuropathy early and adjusting the treatment plan is the most established prevention strategy available. This is not a passive thing. It requires you to report symptoms promptly and your care team to act on them.

Dose reductions and delays can affect cancer outcomes, which is why oncologists are careful with these decisions. But uncontrolled neuropathy can also lead to dose reductions down the line, sometimes at a worse time. ⁹ The best approach involves regular neurological assessments during treatment, combining objective nerve testing with your own reports of symptoms, so that problems are caught before they become irreversible. ¹⁰

If you are midway through a chemo cycle and notice increasing numbness in your fingertips, a new burning sensation in your feet, or difficulty picking up small objects, do not wait for your next scheduled appointment. These are the warning signs that trigger the conversation about whether your dose needs to change.

Exercise During Chemotherapy

Physical activity during chemo is the closest thing to a proven non-pharmacological preventive measure, and the evidence for it has grown meaningfully in recent years. A meta-analysis of randomized trials found that patients who exercised had significantly better outcomes across neuropathy symptom scores, numbness, tingling, pain, balance, and quality of life compared with those who did not exercise. ¹¹ Balance, which is heavily affected by nerve damage to the feet, showed a particularly large improvement in exercising groups.

A multicenter trial found that exercise reduced specific CIPN symptoms like hot and cold sensations in the hands and feet, with some evidence of reduced numbness and tingling as well. The benefits appeared greater for patients who were older or male. ¹² A separate randomized trial using sensorimotor training and resistance exercise found that patients who stuck with the program closely (attending at least two-thirds of sessions) reported less worsening of sensory symptoms in their feet. Those adherent exercisers also maintained greater muscle strength and quality of life and were able to receive a higher proportion of their planned chemo dose. ¹³

That last point is worth emphasizing: exercise did not just reduce symptoms, it helped patients tolerate more of their cancer treatment. The programs studied generally include a mix of aerobic activity, resistance training, and balance exercises. You do not need to be an athlete. Walking, light weights, and simple balance drills performed several times per week are the kinds of activities that showed up in these trials. The key, based on the data, is consistency throughout treatment rather than intensity.

Cryotherapy and Frozen Gloves

Cooling the hands and feet during chemotherapy infusions is an appealing idea: by constricting blood vessels, you reduce how much of the drug reaches the peripheral nerves in those areas. In practice, the evidence is mixed, and the research community has not reached a consensus.

A meta-analysis of frozen gloves specifically found no statistically significant reduction in either sensory or motor neuropathy across multiple measurement tools. ¹⁴ A broader systematic review of cryotherapy methods came to a similar conclusion, finding that the evidence is conflicting, though it noted that cryotherapy was generally well tolerated and caused no serious side effects. ¹⁵ However, a more recent systematic review covering a wider range of cold therapy methods found that cold therapy was effective in preventing CIPN in more than half of the included studies, with the benefits appearing most consistently in patients receiving taxane-based chemotherapy. ¹⁶

The disagreement across studies likely comes from differences in how the cold was applied (frozen gloves versus cooling systems versus crushed ice), how long the cooling lasted, and how neuropathy was measured. If your infusion center offers cooling gloves or socks, trying them is reasonable given the lack of serious risks. But go in with realistic expectations: this is a maybe, not a proven intervention.

Compression Therapy With Surgical Gloves

A more unusual approach involves wearing tight surgical gloves during chemotherapy infusions. The idea is that squeezing the fingers reduces microvascular blood flow to the fingertips, limiting how much drug reaches those nerves. An early multicenter study using surgical gloves during nanoparticle albumin-bound paclitaxel (nab-paclitaxel) infusions found dramatically lower rates of neuropathy in the gloved hand compared with the ungloved hand. ¹⁷

The catch: that study was not blinded, and patients wore gloves that were deliberately too small, which may have increased the compression effect but also made the approach uncomfortable. When a more rigorous double-blind trial tested normal-sized surgical gloves with standard paclitaxel, compression therapy showed no significant benefit for preventing peripheral neuropathy. ¹⁸ A subsequent randomized controlled trial aimed to clarify this discrepancy. ¹⁹ Compression therapy is extremely cheap (about sixty cents per pair of gloves), but the evidence supporting it has weakened considerably since the initial enthusiasm.

Supplements and Antioxidants

This is an area where patient hope collides with disappointing data. The idea that antioxidants might protect nerves from chemotherapy-induced oxidative damage sounds logical, and several supplements have been put through trials. The results have been almost uniformly negative.

Alpha-lipoic acid (ALA) is one of the most frequently asked about. A randomized, double-blind, placebo-controlled trial found no significant difference between ALA and placebo on any measure of neuropathy symptoms, pain, or function over 24 weeks. ²⁰ A systematic review of diet and supplements for neuropathic pain confirmed that ALA was not effective for CIPN and went further, finding that acetyl-L-carnitine was likely ineffective or even harmful. Results for vitamin B12, vitamin E, glutamine, and the Japanese herbal remedy goshajinkigan were mixed, with at least one study finding goshajinkigan harmful as well. ²¹

The ASCO guideline is unambiguous on one specific supplement: acetyl-L-carnitine should be actively discouraged for CIPN prevention. ⁸ This is not just a “probably doesn’t help” situation; a randomized trial found it actually worsened neuropathy. If you are taking it, bring this up with your oncologist. No other review of agents including amifostine, glutathione, or vitamin E has shown clear efficacy for prevention either. ²²

What About Acupuncture

Acupuncture has shown some promise for treating CIPN that already exists, but for prevention during chemotherapy, the picture is more complicated. A pilot randomized trial in breast cancer survivors with established CIPN found that acupuncture improved sensory symptoms, neurotoxicity scores, and pain severity compared with usual care. ²³ However, that was a treatment trial, not a prevention trial.

When electroacupuncture was tested specifically for prevention of taxane-induced neuropathy in a sham-controlled trial, something concerning happened. Both groups reported worsening pain during treatment, with no difference between real and sham acupuncture at the end of chemotherapy. But at a follow-up four weeks later, the group that received real electroacupuncture actually recovered more slowly than the sham group. The study’s own authors concluded that future research should focus on acupuncture for treatment rather than prevention. ²⁴ A more recent Chinese randomized trial did report that electroacupuncture sharply reduced the incidence of CIPN at 24 weeks compared with usual care. ²⁵ These conflicting results make it hard to give a clean recommendation. If you are interested in acupuncture, it is more clearly supported for managing existing symptoms than for prevention.

Medications Being Explored for Prevention

Duloxetine is the only medication with strong enough evidence to be recommended for treating painful CIPN that has already developed, though even its benefit is described as limited. ²⁶ Researchers have recently started asking whether starting duloxetine before or during chemo might prevent neuropathy from developing. A small randomized trial in breast cancer patients receiving paclitaxel found that the placebo group developed new neuropathy at roughly twice the rate of the duloxetine group, with some nerve conduction measures supporting the protective effect. ²⁷ This is a single small trial, so it is too early to recommend duloxetine as a standard preventive measure, but it is the kind of signal researchers are watching.

Venlafaxine, another antidepressant in the same drug class, was tested in patients receiving oxaliplatin and showed less acute neurotoxicity compared with placebo in one trial. ²² Calcium and magnesium infusions have also been studied for oxaliplatin-based regimens with some positive results, though concerns about whether they might reduce chemotherapy effectiveness have not been fully resolved.

Topical Options for Symptom Relief

While these are primarily treatments rather than prevention, two topical approaches are worth knowing about because they can reduce the symptom burden of early neuropathy and potentially support the case for continuing chemo at full dose. High-concentration capsaicin patches, applied to affected areas, have shown some ability to normalize nerve fiber density in skin biopsies, suggesting a genuine regenerative effect rather than just pain masking. ²⁸ Topical menthol applied to the hands and feet has also shown significant improvement in CIPN symptoms in a randomized controlled trial of breast cancer patients. ²⁹ These are low-risk and inexpensive enough to consider alongside other approaches.

The Financial Weight of Neuropathy

CIPN is not just a medical burden. Patients with chemotherapy-associated neuropathy incur substantially higher healthcare costs than those without it, driven by more outpatient visits and longer hospital stays. ³⁰ An economic review estimated that indirect costs, including lost wages and caregiver work loss, account for roughly 86% of total CIPN-related costs per episode. The caregiver’s lost income alone made up the largest share of those indirect costs. ³¹ These numbers underline why even partial prevention matters. Every strategy that reduces the severity of neuropathy by even one grade can translate into real financial relief for patients and families.

CIPN in Children and Long-Term Survivors

Most CIPN research focuses on adults, but children and adolescents on vincristine, platinum agents, or taxanes also face nerve damage. The clinical picture in younger patients can be harder to detect because children may not articulate subtle sensory changes, and assessment tools designed for adults do not always translate well. ³²

A study of long-term childhood cancer survivors found that those exposed to neurotoxic chemotherapy had widespread reductions in sensory nerve function on objective testing, even years later. About a quarter had nerve measurements below normal population ranges, suggesting permanent loss of functioning nerve fibers. Motor nerves appeared to recover better than sensory nerves over time, and the neuropathy observed at long follow-up was predominantly sensory in nature. ³³ For parents of children in treatment, the same general advice applies: report symptoms early, and ask the oncology team about dose adjustments if neuropathy symptoms emerge. The exercise data from adult trials has not been fully replicated in pediatric populations, but staying physically active during treatment is generally encouraged for children as well.